| 1.86 -0.08 (-4.12%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 2.37 | 1-year : | 2.56 |
| Resists | First : | 2.03 | Second : | 2.2 |
| Pivot price | 1.92 |
|||
| Supports | First : | 1.76 | Second : | 1.47 |
| MAs | MA(5) : | 1.93 |
MA(20) : | 1.92 |
| MA(100) : | 2.56 |
MA(250) : | 8.61 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1  |
| %K %D | K(14,3) : | 35.1 |
D(3) : | 46 |
| RSI | RSI(14): 39.7 |
|||
| 52-week | High : | 31 | Low : | 1.76 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ GNPX ] has closed above bottom band by 24.3%. Bollinger Bands are 71.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 20 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.99 - 2 | 2 - 2.01 |
| Low: | 1.78 - 1.79 | 1.79 - 1.8 |
| Close: | 1.85 - 1.86 | 1.86 - 1.87 |
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
Mon, 13 May 2024
New Company Officers Appointed After Promising Preclinical - openPR
Wed, 08 May 2024
Genprex Announces the Passing of its Co-Founder and Chief Executive Officer, Rodney Varner - PR Newswire
Tue, 19 Mar 2024
Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - Quantisnow
Tue, 06 Feb 2024
Genprex Launches Phase 2a Reqorsa Trial Expansion - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 2 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 1.6 (%) |
| Held by Institutions | 6.8 (%) |
| Shares Short | 51 (K) |
| Shares Short P.Month | 47 (K) |
| EPS | -18.81 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.55 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -96.9 % |
| Return on Equity (ttm) | -202.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -13.24 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -23 (M) |
| Levered Free Cash Flow | -13 (M) |
| PE Ratio | -0.1 |
| PEG Ratio | 0 |
| Price to Book value | 0.4 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.17 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|